Zacks Investment Research downgraded shares of Pharma Mar (NASDAQ:PHMMF) from a buy rating to a hold rating in a report issued on Saturday.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Pharma Mar (NASDAQ PHMMF) opened at 4.17 on Friday. Pharma Mar has a 52-week low of $2.40 and a 52-week high of $4.80. The stock’s market cap is $1.03 billion. The company has a 50-day moving average price of $4.42 and a 200 day moving average price of $4.09.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Lowers Pharma Mar (PHMMF) to Hold” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/09/20/zacks-investment-research-lowers-pharma-mar-phmmf-to-hold.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.